Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform

This UK population-based cohort study (n=194,637; 15.7% received ≥2 hydroxychloroquine prescriptions) found no difference in estimated standardised Covid-19 mortality between those receiving hydroxychloroquine before the pandemic and those not (HR 1.03; 95% CI 0.80-1.33).

Source:

The Lancet Rheumatology